Bexxar: Missing the second shoe

When it struck a deal to acquire Coulter Pharmaceutical Inc. last year for $570 million in stock, Corixa Corp. tried to cover its bases with an opt out of the takeover if the FDA failed to accept Coulter's BLA for Bexxar, a radiolabeled anti-CD20 monoclonal antibody to treat non-Hodgkin's lymphoma.

The exit clause may have been prudent, given that Bexxar had gone nowhere at the

Read the full 644 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE